Marco Moia

Marco Moia

Auto-generated profile, based on publicly available information

Marco Moia

Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, A Bianchi Bonomi, Milan, Italy

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1996 in The Lancet
Verified
Journal Article
Closed access
GPGualtiero Palareti
Gualtiero Palareti
NLNicoletta Leali
Nicoletta Leali
SCSergio Coccheri
Sergio Coccheri
MPMario Poggi
Mario Poggi
CMCesare Manotti
Cesare Manotti
SMSerena Musolesi
Serena Musolesi

1 January 2006 in Annals of Surgery
Verified
Journal Article
Closed access
GAGiancarlo Agnelli
Giancarlo Agnelli
GBGiorgio Bolis
Giorgio Bolis
LCLorenzo Capussotti
Lorenzo Capussotti
RSRoberto Mario Scarpa
Roberto Mario Scarpa
FTFrancesco Tonelli
Francesco Tonelli
GGGualberto Gussoni
Gualberto Gussoni
The epidemiology of venous thromboembolism (VTE) after cancer surgery is based on clinical trials on VTE prophylaxis that used venography to screen deep vein thrombosis (DVT). However, the clinical relevance of asymptomatic venography-detected DVT is unclear, and the population of these clinical trials is not necessarily representative of the overall cancer surgery population. The aim of this study was to evaluate the incidence of clinically overt VTE in a wide spectrum of consecutive patients undergoing surgery for cancer and to identify risk factors for VTE. @RISTOS was a prospective observational study in patients undergoing general, urologic, or gynecologic surgery. Patients were assessed for clinically overt VTE occurring up to 30 ± 5 days after surgery or more if the hospital stay was longer than 35 days. All outcome events were evaluated by an independent Adjudication Committee. A total of 2373 patients were included in the study: 1238 (52%) undergoing general, 685 (29%) urologic, and 450 (19%) gynecologic surgery. In-hospital prophylaxis was given in 81.6% and postdischarge prophylaxis in 30.7% of the patients. Fifty patients (2.1%) were adjudicated as affected by clinically overt VTE (DVT, 0.42%; nonfatal pulmonary embolism, 0.88%; death 0.80%). The incidence of VTE was 2.83% in general surgery, 2.0% in gynecologic surgery, and 0.87% in urologic surgery. Forty percent of the events occurred later than 21 days from surgery. The overall death rate was 1.72%; in 46.3% of the cases, death was caused by VTE. In a multivariable analysis, 5 risk factors were identified: age above 60 years (2.63, 95% confidence interval, 1.21–5.71), previous VTE (5.98, 2.13–16.80), advanced cancer (2.68, 1.37–5.24), anesthesia lasting more than 2 hours (4.50, 1.06–19.04), and bed rest longer than 3 days (4.37, 2.45–7.78). VTE remains a common complication of cancer surgery, with a remarkable proportion of events occurring late after surgery. In patients undergoing cancer surgery, VTE is the most common cause of death at 30 days after surgery.

24 May 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CBCecilia Becattini
Cecilia Becattini
GAGiancarlo Agnelli
Giancarlo Agnelli
ASAlessandro Schenone
Alessandro Schenone
SESabine Eichinger
Sabine Eichinger
EBEugenio Bucherini
Eugenio Bucherini
PPPaolo Prandoni
Paolo Prandoni
About 20% of patients with unprovoked venous thromboembolism have a recurrence within 2 years after the withdrawal of oral anticoagulant therapy. Extending anticoagulation prevents recurrences but is associated with increased bleeding. The benefit of aspirin for the prevention of recurrent venous thromboembolism is unknown. In this multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment were randomly assigned to aspirin, 100 mg daily, or placebo for 2 years, with the option of extending the study treatment. The primary efficacy outcome was recurrence of venous thromboembolism, and major bleeding was the primary safety outcome. Venous thromboembolism recurred in 28 of the 205 patients who received aspirin and in 43 of the 197 patients who received placebo (6.6% vs. 11.2% per year; hazard ratio, 0.58; 95% confidence interval [CI], 0.36 to 0.93) (median study period, 24.6 months). During a median treatment period of 23.9 months, 23 patients taking aspirin and 39 taking placebo had a recurrence (5.9% vs. 11.0% per year; hazard ratio, 0.55; 95% CI, 0.33 to 0.92). One patient in each treatment group had a major bleeding episode. Adverse events were similar in the two groups. Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding. (Funded by the University of Perugia and others; WARFASA ClinicalTrials.gov number, NCT00222677.)

19 July 2001 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GAGiancarlo Agnelli
Giancarlo Agnelli
PPPaolo Prandoni
Paolo Prandoni
MSMaria Gabriella Santamaria
Maria Gabriella Santamaria
PBPaola Bagatella
Paola Bagatella
AIAlfonso Iorio
Alfonso Iorio
TIthe Warfarin Optimal Duration Italian Trial Investigators
the Warfarin Optimal Duration Italian Trial Investigators
In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated with a reduced incidence of recurrent thrombosis during the period of therapy. Whether this benefit persists after anticoagulant therapy is discontinued is controversial. Patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy were randomly assigned to the discontinuation of oral anticoagulants or to their continuation for nine additional months. The primary study outcome was recurrence of symptomatic, objectively confirmed venous thromboembolism during at least two years of follow-up. The primary intention-to-treat analysis showed that of 134 patients assigned to continued oral anticoagulant therapy, 21 had a recurrence of venous thromboembolism (15.7 percent; average follow-up, 37.8 months), as compared with 21 of 133 patients assigned to the discontinuation of oral anticoagulant therapy (15.8 percent; average follow-up, 37.2 months), resulting in a relative risk of 0.99 (95 percent confidence interval, 0.57 to 1.73). During the initial nine months after randomization (after all patients received three months of therapy), 1 patient had a recurrence while receiving oral anticoagulant therapy (0.7 percent), as compared with 11 of the patients assigned to the discontinuation of oral anticoagulant therapy (8.3 percent, P=0.003). The incidence of recurrence after the discontinuation of treatment was 5.1 percent per patient-year in patients in whom oral anticoagulant therapy was discontinued after 3 months and 5.0 percent per patient-year in patients who received an additional 9 months of oral anticoagulant therapy. None of the recurrences were fatal. Four patients had nonfatal major bleeding during the extended period of anticoagulant therapy (3.0 percent). In patients with idiopathic deep venous thrombosis, the clinical benefit associated with extending the duration of anticoagulant therapy to one year is not maintained after the therapy is discontinued.

1 May 1996 in The American Journal of Medicine
Verified
Journal Article
Closed access
GFGuido Finazzi
Guido Finazzi
VBVincenzo Brancaccio
Vincenzo Brancaccio
MMMarco Moia
Marco Moia
NCNicola Ciavarella
Nicola Ciavarella
MMM. Gabriella Mazzucconi
M. Gabriella Mazzucconi
TBTiziano Barbui
Tiziano Barbui

29 October 2010 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
WSW. Saber
W. Saber
TMT. Moua
T. Moua
EWE. C. Williams
E. C. Williams
MVM. Verso
M. Verso
GAG. Agnelli
G. Agnelli
ALA. Y. Lee
A. Y. Lee